schliessen

Filtern

 

Bibliotheken

Dietary Supplement Hymecromone and Sorafenib: A Novel Combination for the Control of Renal Cell Carcinoma.(Report)

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.juro.2012.12.011 Byline: Anaid Benitez (a), Travis J. Yates (a), N. Shamaldevi (b), Tim Bowen (d), Vinata B. Lokeshwar (a)(b)(c) Keywords: kidney; carcinoma, renal cell; hymecromone; sorafenib; neoplasm invasi... Full description

Journal Title: The Journal of Urology July, 2013, Vol.190(1), p.285(6)
Main Author: Benitez, Anaid
Other Authors: Yates, Travis J. , Shamaldevi, N. , Bowen, Tim , Lokeshwar, Vinata B.
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0022-5347
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: gale_ofa341418997
title: Dietary Supplement Hymecromone and Sorafenib: A Novel Combination for the Control of Renal Cell Carcinoma.(Report)
format: Article
creator:
  • Benitez, Anaid
  • Yates, Travis J.
  • Shamaldevi, N.
  • Bowen, Tim
  • Lokeshwar, Vinata B.
subjects:
  • Vascular Endothelial Growth Factor
  • Renal Cell Carcinoma
  • Antineoplastic Agents
  • Dietary Supplements
  • Epidermal Growth Factors
  • Cells (Biology)
  • Hyaluronic Acid
  • Drug Approval
ispartof: The Journal of Urology, July, 2013, Vol.190(1), p.285(6)
description: To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.juro.2012.12.011 Byline: Anaid Benitez (a), Travis J. Yates (a), N. Shamaldevi (b), Tim Bowen (d), Vinata B. Lokeshwar (a)(b)(c) Keywords: kidney; carcinoma, renal cell; hymecromone; sorafenib; neoplasm invasiveness Abbreviations: EC, endothelial cell; EGF, epidermal growth factor; EGFR, EGF receptor; HA, hyaluronic acid; HC, hymecromone; HLF, human lung fibroblast; HMVEC-L, human microvascular endothelial cells-lung; HUVEC, human umbilical vein endothelial cells; mRCC, metastatic RCC; O.D., optical density; p-, phospho-; RCC, renal cell carcinoma; SF, sorafenib; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor Abstract: Current treatments for metastatic renal cell carcinoma do not extend survival beyond a few months. Sorafenib is a targeted drug approved for metastatic renal cell carcinoma but it has modest efficacy. Hymecromone is a nontoxic dietary supplement with some antitumor activity at high doses of 450 to 3,000 mg per day. Hymecromone inhibits the synthesis of hyaluronic acid, which promotes tumor growth and metastasis. We recently noted that the hyaluronic acid receptors CD44 and RHAMM are potential predictors of metastatic renal cell carcinoma. In the current study we examined the antitumor properties of hymecromone, sorafenib and the combination in renal cell carcinoma models. Author Affiliation: (a) Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, Miami, Florida (b) Department of Urology, University of Miami-Miller School of Medicine, Miami, Florida (c) Department of Cell Biology, University of Miami-Miller School of Medicine, Miami, Florida (d) Section of Nephrology, Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom Article History: Received 6 December 2012 Article Note: (footnote) Study received institutional animal care and use committee approval., Supported by R01 CA 72821-11 and The Woman's Cancer Association of the University of Miami (VBL).
language: English
source:
identifier: ISSN: 0022-5347
fulltext: fulltext
issn:
  • 0022-5347
  • 00225347
url: Link


@attributes
ID688461226
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid341418997
sourceidgale_ofa
recordidTN_gale_ofa341418997
sourceformatXML
sourcesystemOther
pqid1367880938
galeid341418997
display
typearticle
titleDietary Supplement Hymecromone and Sorafenib: A Novel Combination for the Control of Renal Cell Carcinoma.(Report)
creatorBenitez, Anaid ; Yates, Travis J. ; Shamaldevi, N. ; Bowen, Tim ; Lokeshwar, Vinata B.
ispartofThe Journal of Urology, July, 2013, Vol.190(1), p.285(6)
identifierISSN: 0022-5347
subjectVascular Endothelial Growth Factor ; Renal Cell Carcinoma ; Antineoplastic Agents ; Dietary Supplements ; Epidermal Growth Factors ; Cells (Biology) ; Hyaluronic Acid ; Drug Approval
descriptionTo link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.juro.2012.12.011 Byline: Anaid Benitez (a), Travis J. Yates (a), N. Shamaldevi (b), Tim Bowen (d), Vinata B. Lokeshwar (a)(b)(c) Keywords: kidney; carcinoma, renal cell; hymecromone; sorafenib; neoplasm invasiveness Abbreviations: EC, endothelial cell; EGF, epidermal growth factor; EGFR, EGF receptor; HA, hyaluronic acid; HC, hymecromone; HLF, human lung fibroblast; HMVEC-L, human microvascular endothelial cells-lung; HUVEC, human umbilical vein endothelial cells; mRCC, metastatic RCC; O.D., optical density; p-, phospho-; RCC, renal cell carcinoma; SF, sorafenib; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor Abstract: Current treatments for metastatic renal cell carcinoma do not extend survival beyond a few months. Sorafenib is a targeted drug approved for metastatic renal cell carcinoma but it has modest efficacy. Hymecromone is a nontoxic dietary supplement with some antitumor activity at high doses of 450 to 3,000 mg per day. Hymecromone inhibits the synthesis of hyaluronic acid, which promotes tumor growth and metastasis. We recently noted that the hyaluronic acid receptors CD44 and RHAMM are potential predictors of metastatic renal cell carcinoma. In the current study we examined the antitumor properties of hymecromone, sorafenib and the combination in renal cell carcinoma models. Author Affiliation: (a) Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, Miami, Florida (b) Department of Urology, University of Miami-Miller School of Medicine, Miami, Florida (c) Department of Cell Biology, University of Miami-Miller School of Medicine, Miami, Florida (d) Section of Nephrology, Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom Article History: Received 6 December 2012 Article Note: (footnote) Study received institutional animal care and use committee approval., Supported by R01 CA 72821-11 and The Woman's Cancer Association of the University of Miami (VBL).
languageEnglish
source
version5
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
scope
0gale_onefilea
1OneFile
creatorcontrib
0Benitez, Anaid
1Anaid Benitez
2Yates, Travis J
3Shamaldevi, N
4Bowen, Tim
5Lokeshwar, Vinata B
titleDietary Supplement Hymecromone and Sorafenib: A Novel Combination for the Control of Renal Cell Carcinoma.(Report)
descriptionTo link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.juro.2012.12.011 Byline: Anaid Benitez (a), Travis J. Yates (a), N. Shamaldevi (b), Tim Bowen (d), Vinata B. Lokeshwar (a)(b)(c) Keywords: kidney; carcinoma, renal cell; hymecromone; sorafenib; neoplasm invasiveness Abbreviations: EC, endothelial cell; EGF, epidermal growth factor; EGFR, EGF receptor; HA, hyaluronic acid; HC, hymecromone; HLF, human lung fibroblast; HMVEC-L, human microvascular endothelial cells-lung; HUVEC, human umbilical vein endothelial cells; mRCC, metastatic RCC; O.D., optical density; p-, phospho-; RCC, renal cell carcinoma; SF, sorafenib; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor Abstract: Current treatments for metastatic renal cell carcinoma do not extend survival beyond a few months. Sorafenib is a targeted drug approved for metastatic renal cell carcinoma but it has modest efficacy. Hymecromone is a nontoxic dietary supplement with some antitumor activity at high doses of 450 to 3,000 mg per day. Hymecromone inhibits the synthesis of hyaluronic acid, which promotes tumor growth and metastasis. We recently noted that the hyaluronic acid receptors CD44 and RHAMM are potential predictors of metastatic renal cell carcinoma. In the current study we examined the antitumor properties of hymecromone, sorafenib and the combination in renal cell carcinoma models. Author Affiliation: (a) Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, Miami, Florida (b) Department of Urology, University of Miami-Miller School of Medicine, Miami, Florida (c) Department of Cell Biology, University of Miami-Miller School of Medicine, Miami, Florida (d) Section of Nephrology, Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom Article History: Received 6 December 2012 Article Note: (footnote) Study received institutional animal care and use committee approval., Supported by R01 CA 72821-11 and The Woman's Cancer Association of the University of Miami (VBL).
subject
0Vascular endothelial growth factor
1Renal cell carcinoma
2Antineoplastic agents
3Dietary supplements
4Epidermal growth factors
5Cells (Biology)
6Hyaluronic acid
7Drug approval
82834
92833
10Pharmaceutical preparations
11Medicinals and botanicals
12Pharmaceutical Preparation Manufacturing
13Biological Product (except Diagnostic) Manufacturing
14325412
15325414
16Carcinoma, Renal cell
17Antimitotic agents
18Epidermal growth factor
19Cells
general
0English
1Elsevier B.V.
2Cengage Learning, Inc.
sourceidgale_ofa
recordidgale_ofa341418997
issn
00022-5347
100225347
rsrctypearticle
creationdate2013
recordtypearticle
addtitleThe Journal of Urology
searchscopeOneFile
lsr30VSR-Enriched:[doi, galeid, pages, eissn, date, pqid]
sort
titleDietary Supplement Hymecromone and Sorafenib: A Novel Combination for the Control of Renal Cell Carcinoma.(Report)
authorBenitez, Anaid ; Yates, Travis J. ; Shamaldevi, N. ; Bowen, Tim ; Lokeshwar, Vinata B.
creationdate20130701
facets
frbrgroupid-321923313303514851
frbrtype5
languageeng
creationdate2013
topic
0Vascular Endothelial Growth Factor
1Renal Cell Carcinoma
2Antineoplastic Agents
3Dietary Supplements
4Epidermal Growth Factors
5Cells (Biology)
6Hyaluronic Acid
7Drug Approval
collectionOneFile (GALE)
prefilterarticles
rsrctypearticles
creatorcontrib
0Benitez, Anaid
1Yates, Travis J.
2Shamaldevi, N.
3Bowen, Tim
4Lokeshwar, Vinata B.
jtitleJournal of Urology
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Benitez, Anaid
1Yates, Travis J.
2Shamaldevi, N.
3Bowen, Tim
4Lokeshwar, Vinata B.
atitleDietary Supplement Hymecromone and Sorafenib: A Novel Combination for the Control of Renal Cell Carcinoma.(Report)
jtitleThe Journal of Urology
risdate20130701
volume190
issue1
spage285
issn0022-5347
genrearticle
ristypeJOUR
abstractTo link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.juro.2012.12.011 Byline: Anaid Benitez (a), Travis J. Yates (a), N. Shamaldevi (b), Tim Bowen (d), Vinata B. Lokeshwar (a)(b)(c) Keywords: kidney; carcinoma, renal cell; hymecromone; sorafenib; neoplasm invasiveness Abbreviations: EC, endothelial cell; EGF, epidermal growth factor; EGFR, EGF receptor; HA, hyaluronic acid; HC, hymecromone; HLF, human lung fibroblast; HMVEC-L, human microvascular endothelial cells-lung; HUVEC, human umbilical vein endothelial cells; mRCC, metastatic RCC; O.D., optical density; p-, phospho-; RCC, renal cell carcinoma; SF, sorafenib; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor Abstract: Current treatments for metastatic renal cell carcinoma do not extend survival beyond a few months. Sorafenib is a targeted drug approved for metastatic renal cell carcinoma but it has modest efficacy. Hymecromone is a nontoxic dietary supplement with some antitumor activity at high doses of 450 to 3,000 mg per day. Hymecromone inhibits the synthesis of hyaluronic acid, which promotes tumor growth and metastasis. We recently noted that the hyaluronic acid receptors CD44 and RHAMM are potential predictors of metastatic renal cell carcinoma. In the current study we examined the antitumor properties of hymecromone, sorafenib and the combination in renal cell carcinoma models. Author Affiliation: (a) Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, Miami, Florida (b) Department of Urology, University of Miami-Miller School of Medicine, Miami, Florida (c) Department of Cell Biology, University of Miami-Miller School of Medicine, Miami, Florida (d) Section of Nephrology, Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom Article History: Received 6 December 2012 Article Note: (footnote) Study received institutional animal care and use committee approval., Supported by R01 CA 72821-11 and The Woman's Cancer Association of the University of Miami (VBL).
pubElsevier B.V.
lad01gale_ofa
doi10.1016/j.juro.2012.12.011
pages285-290
eissn15273792
date2013-07